The pipeline and the porcupine: Alternate metaphors of the physician-industry relationship

Social Science and Medicine

Volumn 60, Issue 6, 2005, Pages 1323-1334

  Mather, Charles ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Canada; Cultural capital; Gift exchange; Pharmaceuticals; Physician industry relationship

Indexed keywords

PHARMACEUTICAL INDUSTRY;

ARTICLE; CANADA; CLINICAL PRACTICE; DEMOGRAPHY; DRUG INDUSTRY; HUMAN; INDUSTRY; MEDICAL SCHOOL; PHYSICIAN ATTITUDE;

ALBERTA; ATTITUDE; BIOMEDICAL RESEARCH; CONFLICT OF INTEREST; DRUG INDUSTRY; ECONOMICS, MEDICAL; GIFT GIVING; HOSPITALS, TEACHING; HUMANS; INFORMATION DISSEMINATION; INTERINSTITUTIONAL RELATIONS; INTERNSHIP AND RESIDENCY; INTERVIEWS; MARKETING; METAPHOR; MODELS, ECONOMIC;

EID: 11144311089     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2004.07.011     Document Type: Article

References (58)

1. S. Andreaopoulos The unhealthy alliance between academia and corporate America Western Journal of Medicine 175 2001 225 226
2. AMA (2001). E-8.061 Gifts to Physicians From Industry. URL: http://www.ama-assn.org/ama/pub/article/4001-4236.html.
3. S.S. Andaleeb, and R.F. Tallman Physician attitudes toward pharmaceutical sales representatives Health Care Management Review 20 3 1995 68 76
4. M. Angell The pharmaceutical industry - to whom is it accountable? New England Journal of Medicine 342 25 2000 1902 1904
5. M. Angell Is academic medicine for sale New England Journal of Medicine 342 20 2000 1516 1518
6. Anonymous (1990). Hippocrates meet Mammon. The Economist, Sep 22, 95.
7. A. Appadurai The Social Life of Things commodities in Cultural Perspective 1986 Cambridge University Press Cambridge, England
8. J.W. Banks, and A.G. Mainous Attitudes of medical school faculty toward gifts from the pharmaceutical industry Academic Medicine 67 9 1992 610 612
9. J.E. Bekelman, Y. Li, and C.P. Gross Scope and impact of financial conflicts of interest in biomedical research a systematic review Journal of American Medical Association 289 2003 454 465
10. L.A. Bero, A. Galbraith, and D. Rennie The publication of sponsored symposiums in medical journals New England Journal of Medicine 327 16 1992 1135 1140
11. D. Blumenthal, N. Causino, E. Campbell, and K. Seashore Relationships between academic institutions and industry in the life sciences New England Journal of Medicine 334 6 1996 368 374
12. D. Blumenthal, E. Campbell, N. Causino, and K. Seashore Louis Participation of life-science faculty in research relationships with industry New England Journal of Medicine 335 23 1996 1734 1739
13. W.C. Bogner, and H. Thomas Drugs to Market creating Value and Advantage in the Pharmaceutical Industry 1996 Pergamon New York
14. P. Bourdieu Distinction critique sociale du jugement 1984 Routledge & Kegan Paul London Translated by Richard Nice
15. M.A. Bowman, and D.L. Pearle Changes in drug prescribing patterns related to commercial company funding of continuing medical education Journal of Continuing Education in the Health Professions 8 1 1988 13 20
16. E. Boyd, and L. Bero Assessing faculty financial relationships with industry Journal of American Medical Association 284 2000 2209 2214
17. B. Burton, and A. Rowell Unhealthy spin British Medical Journal 326 2003 1205 1207
18. T.S. Caudill, M.S. Johnson, E.C. Rich, and W.P. McKinney Physicians, pharmaceutical sales representatives, and the cost of prescribing Archives of Family Medicine 5 4 1996 201 206
19. M.K. Cho, and L.A. Bero The quality of drug studies published in symposium proceedings Annals of Internal Medicine 124 5 1996 485 489
20. M.M. Chren, and C.S. Landefeld Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary Journal of American Medical Association 271 9 1994 684 689
21. CMA Physicians and the pharmaceutical industry (update 2001) Canadian Medical Association Journal 164 9 2001 1339 1341
22. A. Darr Gifting practices and interorganizational relations constructing obligation networks in the electronics sector Sociological Forum 18 1 2003 31 51
23. R.A. Davidson Source of funding and outcome of clinical trials Journal of General Internal Medicine 1 3 1986 155 158
24. U. Fleising In search of Genohype a Content Analysis of Biotechnology Company Documents New Genetics and Society 20 3 2001 239 254
25. E. Gibson, F. Baylis, and S. Lewis Dances with the pharmaceutical industry Canadian Medical Association Journal 166 4 2002 448 450
26. E. Hemminki Content analysis of drug-detailing by pharmaceutical representatives Medical Education 11 3 1977 210 215
27. B. Hodges Interactions with the pharmaceutical industry experiences and attitudes of psychiatry residents, interns and clerks Canadian Medical Association Journal 153 5 1995 553 559
28. S. Holm, and M. Evans Product names and proper claims? More ethical issues in the marketing of drugs British Medical Journal 313 1996 1627 1629
29. J.P. Kassirer Financial indigestion Journal of American Medical Association 284 17 2000 2156 2157
30. S.M. Keim, A.B. Sanders, D.B. Witzke, P. Dyne, and J.W. Fulginiti Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry Annals of Emergency Medicine 22 10 1993 1576 1581
31. J. Lenzer Alteplase for stroke money and optimistic claims buttress the "brain attack" campaign British Medical Journal 324 2002 723 729
32. J. Lexchin Interactions between physicians and the pharmaceutical industry what does the literature say? Canadian Medical Association Journal 149 10 1993 1401 1407
33. J. Lexchin, L.A. Bero, B. Djulbegovic, and O. Clark Pharmaceutical industry sponsorship and research outcome and quality systematic review British Medical Journal 326 2003 1167 1170
34. S. Lewis, P. Baird, R.G. Evans, W.A. Ghali, C.J. Wright, E. Gibson, and F. Baylis Dancing with the porcupine rules for governing the university-industry relationship Canadian Medical Association Journal 165 6 2001 783 785
35. B. Lo, L.E. Wolf, and A. Berkeley Conflict-of-interest policies for investigators in clinical trials New England Journal of Medicine 343 22 2000 1616 1620
36. J.B. Martin, and D.L. Kasper In whose best interest? Breaching the academic-industrial wall New England Journal of Medicine 343 22 2000 1646 1649
37. C. Mather, U. Fleising, and L. Taylor Translating Knowledge from Bench to Bedside the Controversial Social Life of t-PA Risk Management. An International Journal 6 2 2004 47 58
38. M. Mauss The gift forms and functions of exchange in archaic societies 1967 Norton New York (Translated by Ian Cunnison)
39. R. Moynihan Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1 entanglement British Medical Journal 326 2003 1189 1192
40. R. Moynihan Who pays for the pizza Redefining the relationships between doctors and drug companies. 2 disentanglement British Medical Journal 326 2003 1193 1196
41. M.Y. Peay, and E.R. Peay The role of commercial sources in the adoption of a new drug Social Science & Medicine 26 12 1988 1183 1189
42. S.A. Rosenberg Secrecy in medical research New England Journal of Medicine 334 6 1996 392 394
43. W.S. Sandberg, R. Carlos, E.H. Sandberg, and M.F. Roizen The effect of educational gifts from pharmaceutical firms on medical students' recall of company names or products Academic Medicine 72 10 1997 916 918
44. M.D. Sergeant, P.G. Hodgetts, M. Godwin, D.M. Walker, and P. McHenry Interactions with the pharmaceutical industry a survey of family medicine residents in Ontario Canadian Medical Association Journal 155 9 1996 1243 1248
45. J. Smith Food, flattery, and friendship British Medical Journal 326 2003 0 g
46. R. Smith Medical journals and pharmaceutical companies uneasy bedfellows British Medical Journal 326 2003 1202 1205
47. B. Spilker Multinational pharmaceutical companies 1989 Raven Press New York
48. R.W. Springarn, J.A. Berlin, and B.L. Strom When pharmaceutical manufacturers' employees present Grand Rounds, what do residents remember? Academic Medicine 71 1 1996 86 88
49. M. Steinman, M. Shlipak, and S. McPhee Of principles and pens attitudes and practices of medicine housestaff toward pharmaceutical industry promotions Amerian Journal of Medicine 110 2001 551 557
50. H.T. Stelfox, G. Chua, K. O'Rourke, and A.S. Detsky Conflict of interest in the debate over calcium-channel antagonists New England Journal of Medicine 338 2 1998 101 106
51. R.M. Tenery Interactions between physicians and the health care technology industry Journal of American Medical Association 283 3 2000 391 393
52. J.H. Thompson The Olivieri Report. The Complete Text of the Reports of the Independent Inquiry Commissioned by the Canadian Association of University Teachers 2001 J. Lorimer Toronto
53. S. Van der Geest, S.R. Whyte, and A. Hardon The anthropology of pharmaceuticals a biographical approach Annual Review of Anthropology 25 1996 153 178
54. V.A. Wade, P.R. Mansfield, and P.J. McDonald Drug companies' evidence to justify advertising Lancet 8674 1989 1261 1263
55. D.R. Waud Pharmaceutical promotions - a free lunch? New England Journal of Medicine 327 5 1992 351 353
56. A. Wazana Physicians and the pharmaceutical industry is a gift ever just a gift? Journal of American Medical Association 283 3 2000 373 380
57. R.F. Woollard Addressing the pharmaceutical industry's influence on professional behaviour Canadian Medical Association Journal 149 4 1993 403 404
58. M.G. Ziegler, P. Lew, and B.C. Singer The accuracy of drug information from pharmaceutical sales representatives Journal of American Medical Association 273 16 1995 1296 1298